Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in the Jefferies London Healthcare Conference with CEO Richard Paulson hosting a fireside chat. The discussion will be available for on-demand listening starting November 18, 2021, at 3:00 a.m. Eastern Time. A replay will be accessible for 30 days on the company's investor website.
Karyopharm is focused on developing innovative cancer therapies, particularly through its XPOVIO® (selinexor) compound, which is approved for multiple hematologic malignancies.
Karyopharm Therapeutics (KPTI) announced new data from a Phase 2 study of selinexor, an oral SINE compound for myelofibrosis patients previously treated with JAK inhibitors. The study showed a 33% response rate, with significant spleen volume reduction and improved anemia status. Despite ruxolitinib's poor prognosis (14 months survival), selinexor demonstrated durable responses and a well-tolerated safety profile. Karyopharm plans to initiate a new Phase 2 study evaluating selinexor against physician's choice in late 2021. Results will be presented at the ASH 2021 meeting from December 11-14.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported third-quarter 2021 financial results, revealing net product revenue of $26.7 million, a 32% increase from the previous quarter and 25% growth year-over-year. The company highlighted its commercial success with XPOVIO, moving into earlier treatment lines for multiple myeloma. R&D expenses rose to $45.8 million, while the net loss was $51.8 million or $0.69 per share. Karyopharm expects a cash runway into mid-2023, with key upcoming milestones including Phase 3 data from the SIENDO study in endometrial cancer.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the granting of stock options for 171,300 shares to 15 newly-hired employees as of October 29, 2021. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), includes a stock option exercise price of $5.46 per share. The options vest over four years, with 25% vesting at the one-year mark. In instances of a "change in control event," the options are immediately exercisable if employment is terminated for "good reason" or without "cause." Karyopharm specializes in innovative cancer therapies, notably its lead compound, XPOVIO®.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its third quarter 2021 financial results on November 3, 2021. The company's management will host a conference call at 8:30 a.m. ET on the same day to discuss results and updates. Karyopharm focuses on innovative cancer therapies, notably its lead compound, XPOVIO® (selinexor), which is approved for multiple hematologic malignancies in the U.S. and has received conditional authorization in Europe. For details, visit the investor section.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that the first patient has been dosed in the Phase 2 expansion study evaluating eltanexor for myelodysplastic syndrome (MDS). This follows promising Phase 1 results showing a 53% overall response rate and a median overall survival of 9.9 months in high-risk, relapsed MDS patients. The Phase 2 expansion aims to assess eltanexor monotherapy in HMA-refractory MDS patients, with the overall response rate as the primary endpoint. Eltanexor is part of a new approach targeting nuclear export to treat various cancers.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options to 21 newly-hired employees as an inducement for joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). A total of 147,300 shares were awarded, with an exercise price of $5.82 per share, reflecting the stock's closing price on September 30, 2021. The options vest over four years, with a portion becoming immediately exercisable under specific conditions related to employment termination. Karyopharm specializes in pioneering cancer therapies, including its lead compound, XPOVIO®.
On September 7, 2021, Karyopharm Therapeutics (Nasdaq: KPTI) announced its CEO, Richard Paulson, will present at three virtual investor conferences in September. The presentations include:
- H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 AM ET (podium presentation).
- Morgan Stanley 19th Annual Global Healthcare Conference on September 13 at 11:00 AM ET (fireside chat).
- Baird 2021 Global Healthcare Conference on September 14 at 2:00 PM ET (fireside chat).
Karyopharm Therapeutics (NASDAQ: KPTI) announced the granting of stock options as inducements for new hires, including Senior VP Eleonora Goldberg, totaling 100,000 shares for her and 76,700 shares for 16 other new employees. These stock options, with an exercise price of $5.80 per share, vest over four years, with some options becoming immediately exercisable under specific conditions. The company focuses on pioneering cancer therapies, particularly through its SINE compounds, which target nuclear export in cancer treatment and show promise in various diseases.
Karyopharm Therapeutics reported Q2 2021 results, highlighting a 21% increase in XPOVIO revenue, reaching $20.2 million. The company aims for FDA approval for XPOVIO in endometrial cancer by year-end. Despite a net loss of $53.6 million or $0.71 per share, the management noted a strong cash position of $239.3 million as of June 30, 2021, sufficient to fund operations into mid-2023. R&D expenses dropped 20% year-over-year, while SG&A costs rose 18%.
